| Literature DB >> 29803274 |
Abstract
Rapid expansion of therapeutic options have increased the complexity of hemophilia care. Previously, on-demand therapy aimed to reduce morbidity and early mortality; however, now aggressive prophylaxis, particularly in children, encourages an active lifestyle. Accurate diagnosis, recognition of early threats to musculoskeletal health, and optimization of therapy are critical for both males and females affected by hemophilia. The diversity of emerging hemophilia therapies, from modified factor protein concentrates, to gene therapy, to nonfactor hemostatic strategies, provide an exciting opportunity to target unmet needs in the bleeding disorder community.Entities:
Keywords: Bispecific antibody; Bleeding; Factor IX; Factor VIII; Factor concentrate; Gene therapy; Hemarthrosis; Inhibitors
Mesh:
Substances:
Year: 2018 PMID: 29803274 DOI: 10.1016/j.pcl.2018.01.004
Source DB: PubMed Journal: Pediatr Clin North Am ISSN: 0031-3955 Impact factor: 3.278